Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix
Therapeutic Advances in Urology · 2024-01 · 16
DOI: 10.1177/17562872241293779 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Urology, online erschienen am 08.11.2024. Verfasst von Patrick Campbell und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and objectives: Intermittent androgen deprivation therapy (iADT) may result in measurable improvements in quality of life over continuous ADT in patients with advanced prostate cancer (aPC). Here, we studied time to castration and testosterone recovery in real-world patients with aPC undergoing iADT with relugolix. Methods and design: Eligibility criteria for this retrospective study were histologically confirmed through the diagnosis of aPC and initiation of iADT with relugolix. Primary endpoints were time to castrate level of testosterone after relugolix initiation and time to recovery to noncastrate levels after relugolix discontinuation. Results: Overall, 25 patients with aPC were treated with iADT and with relugolix. Median time to serum testosterone 50 ng/dL was 1.4 months [range 0.83–6.57 months] from holding treatment with relugolix. Conclusion: iADT with relugolix is associated with a rapid time to testosterone suppression and recovery. These results may guide patients’ counseling and monitoring of serum testosterone and PSA levels in patients wishing to pursue iADT for aPC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Department of Internal Medicine, Detroit Medical Center Sinai Grace Hospital, Detroit, MI, USA.
- Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Westwood, KS, USA.
- Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
ORCID-Profile: Patrick Campbell
Zitieren
APA
Campbell, P., Gebrael, G., Narang, A., Chehade, C. H., Thomas, V. M., Galarza Fortuna, G., Sayegh, N., Tripathi, N., Tandar, C., Dal, E., Li, H., Swami, U., Agarwal, N., & Maughan, B. L. (2024). Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix. Therapeutic Advances in Urology, 16. https://doi.org/10.1177/17562872241293779
Vancouver
Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, et al. Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix. Therapeutic Advances in Urology. 2024;16. doi:10.1177/17562872241293779
BibTeX
@article{Campbell2024,
author = {Campbell, Patrick and Gebrael, Georges and Narang, Arshit and Chehade, Chadi Hage and Thomas, Vinay Mathew and Galarza Fortuna, Gliceida and Sayegh, Nicolas and Tripathi, Nishita and Tandar, Clara and Dal, Emre and Li, Haoran and Swami, Umang and Agarwal, Neeraj and Maughan, Benjamin L},
title = {Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix},
journal = {Therapeutic Advances in Urology},
year = {2024},
volume = {16},
doi = {10.1177/17562872241293779}
}
EUVIMED